Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

OrbusNeich introduces COMBO Dual Therapy Stent

OrbusNeich today launched the world's first dual therapy stent – the COMBO Dual Therapy Stent – to address the challenges of delayed healing of the coronary artery associated with monotherapy drug eluting stents, the current standard of care for the treatment of coronary artery disease.

27 May 2013

Study analyzes potential usefulness of new treatment to reopen clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents.

22 May 2013

Elixir's DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE (Conformité Européenne) Mark approval for its DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System.

15 May 2013

Elixir Medical receives FDA approval to initiate patient enrollment in EXCELLA III clinical trial in US

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it has received approval from the Food and Drug Administration to initiate patient enrollment in the EXCELLA III clinical trial in the United States at up to 50 institutions with conditions to be addressed in parallel.

8 May 2013

Drug-eluting stents can keep clogged leg arteries open and prevent leg amputation

Drug-eluting stents can keep clogged leg arteries open, preventing amputation of the leg, suggests research being presented at the Society of Interventional Radiology's 38th Annual Scientific Meeting in New Orleans.

15 Apr 2013

Riverside Methodist Hospital treats first PAD patient with Cook Medical's Zilver PTX device

Just weeks after the Food and Drug Administration (FDA) approved Cook Medical's Zilver PTX Drug-Eluting Peripheral Stent, Riverside Methodist Hospital in Columbus, Ohio, has treated the first patient with the device as part of Cook's U.S. commercial launch.

19 Dec 2012

Enrollment complete in Tryton's Pivotal IDE Side Branch Stent trial to treat bifurcation lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced the completion of enrollment in the TRYTON Pivotal IDE trial evaluating the Tryton Side Branch Stent.

26 Nov 2012

FDA approves Cook's Zilver PTX drug-eluting peripheral stent

Angiotech Pharmaceuticals, Inc. announced that its partner Cook Medical, Inc. received approval on November 15, 2012 from the U.S. Food and Drug Administration to market and sell the proprietary Zilver PTX drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.

16 Nov 2012

Cook receives FDA approval for Zilver PTX Drug-Eluting Peripheral Stent to treat PAD

The U.S. Food and Drug Administration approved the Zilver PTX Drug-Eluting Peripheral Stent (Zilver PTX Stent), the first drug-eluting stent indicated to re-open a particular artery in the thigh (femoropopliteal artery) when narrowed or blocked as a result of peripheral artery disease (PAD).

15 Nov 2012

Mesh-covered stent improves restoration of blood flow after PCI in heart attack patients

A clinical trial found that the use of a next generation, micronet, mesh-covered stent demonstrated improved restoration of blood flow to heart tissue, compared to the use of either bare-metal or drug-eluting stents in heart attack patients undergoing angioplasty.

25 Oct 2012

PROTECT: Still no clear winner in the battle of the stent generations

Three-year rates of stent thrombosis with zotarolimus- and sirolimus-eluting stents are low and comparable, show results of the PROTECT trial.

29 Aug 2012

Elixir Medical’s DESyne BD Novolimus Eluting Coronary Stent System receives CE Mark approval

Elixir Medical Corporation, a developer of product platforms that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it has received CE Mark approval for its DESyne BD Novolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

29 Aug 2012

Abbott's XIENCE Xpedition Everolimus Eluting Coronary Stent System receives CE Mark in Europe

Abbott today announced that the XIENCE Xpedition Everolimus Eluting Coronary Stent System received CE Mark in Europe for the treatment of coronary artery disease.

20 Aug 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

Johnson & Johnson second quarter sales decrease 0.7% to $16.5B

Johnson & Johnson today announced sales of $16.5 billion for the second quarter of 2012, a decrease of 0.7% as compared to the second quarter of 2011. Operational results increased 3.5% and the negative impact of currency was 4.2%.

17 Jul 2012

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS S.A., a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing Sirolimus-eluting stent.

From Medtronic 15 Jun 2012

Kona Medical raises $30 million in Series C financing

Kona Medical, Inc. today announced it has raised $30 million in Series C financing to advance its novel hypertension therapy.

31 May 2012

Results from Medtronic’s Resolute DES clinical study on CAD

According to study results to be featured in Sunday's late-breaking clinical trials session at the American Association of Clinical Endocrinologists (AACE) 21st Annual Scientific and Clinical Congress in Philadelphia, the Resolute drug-eluting stent (DES) from Medtronic, Inc. yields strong performance in coronary artery disease (CAD) patients both with and without diabetes through two years of follow-up.

From Medtronic 28 May 2012

Medtronic fourth quarter revenue increases 4% to $4.297 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 27, 2012.

From Medtronic 22 May 2012

Cook Medical introduces drug-eluting peripheral stent to treat lesions in the SFA

Cook Medical, a world leader in minimally invasive medical technologies, has launched a first-of-its-kind drug-eluting peripheral stent in Australia, the Zilver PTX Drug-Eluting Peripheral Stent.

21 May 2012